Sandoz Group AG

Sandoz Group AG

SDZNY
Sandoz Group AGUS flagOther OTC
79.60
USD
-1.55
- -
34.44BMarket Cap
Sandoz Group AG
SDZNY
(Other OTC)

Recent

price

79.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
21.59
23.21
24.14
- -
Revenue per Share
1.97
0.18
- -
- -
Basic EPS, GAAP
1.85
-0.61
0.14
- -
Free Cash Flow per Basic Share
- -
- -
0.5
- -
Dividend per Share
20.3
0.06
0.06
- -
Book Value per Share
-0.3
-1.16
-1.81
- -
Tangible Book Value per Share
431
430
430
- -
Basic Weighted Avg Shares
9,306
9,979
10,384
11,157
Sales/Revenue/Turnover
13.31
3.76
2.96
12.77
Operating Margin (%)
492
525
502
545
Depreciation Expense
848
77
- -
914
Net Income, GAAP
22.87
38.46
- -
24.28
Effective Tax Rate (%)
9.11
0.77
- -
8.19
Profit Margin (%)
-1,938
1,874
1,494
1,270
Working Capital
118
4,230
4,666
5,010
LT Debt
8,760
8,654
8,164
9,385
Total Equity
- -
1.98
- -
7.32
Return on Invested Capital (%)
- -
2.9
- -
20.41
Return on Capital (%)
- -
1.76
- -
3,656
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
14.96%
Free Cash Flow
- -
- -
1,250%
Net Income, GAAP
- -
- -
1,087.01%
Sales/Revenue/Turnover
- -
- -
7.44%
Total Cash Common Dividend
- -
- -
46.51%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9,979
2024
- -
- -
- -
- -
10,384
2025
- -
- -
- -
- -
11,157

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.18
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
- -
Business
Sandoz Group AG operates as a prominent global entity in the realm of generic medications and biosimilars. The company is dedicated to the creation, production, and worldwide distribution of accessible, high-quality pharmaceutical products. Its portfolio encompasses a wide array of generic small-molecule medicines and complex biosimilar alternatives across various therapeutic categories, including cardiovascular, oncology, and central nervous system disorders. Sandoz also delivers active pharmaceutical ingredients and finished dose forms, particularly emphasizing its extensive range of anti-infectives, such as antibiotics. The organization spun off to become an independent public company in October 2023. Established in 1886, Sandoz maintains its headquarters in Basel, Switzerland.

Company News

APIChatGPT
  • FDA set to review Sandoz's generic GLP-1s

  • 3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

  • SDZNY or UTHR: Which Is the Better Value Stock Right Now?

  • Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports

  • Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's What You Should Know

  • USNA or SDZNY: Which Is the Better Value Stock Right Now?

  • Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown

  • Sandoz Group AG (SDZNY) Q1 2026 Sales/Trading Call Transcript

  • USNA vs. SDZNY: Which Stock Is the Better Value Option?

  • All You Need to Know About Sandoz Group AG Sponsored ADR (SDZNY) Rating Upgrade to Buy

  • SGIOY vs. SDZNY: Which Stock Is the Better Value Option?

  • Sandoz Group (OTCMKTS:SDZNY) Trading Down 1.7% – Should You Sell?

  • SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • 3 Generic Drug Stocks to Watch Despite Industry Headwinds

  • Sandoz Shares Jump on Improved Guidance

  • Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript

  • SGIOY or SDZNY: Which Is the Better Value Stock Right Now?

  • Sandoz: The Share Price May Have Run Its Course

  • Sandoz Group (OTCMKTS:SDZNY) versus Context Therapeutics (NASDAQ:CNTX) Head-To-Head Contrast

  • Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript